EGFR and non-small cell lung carcinoma: In addition, ChiCTR1800019185 is a single-arm clinical trial that evaluates the PFS of combining Apatinib with EGFR TKI in NSCLC with slow progression following EGFR-TKI first-line therapy.[34]